Abstract
Background: Fibromyalgia is a complex pain-focused syndrome. Previous studies showed that Cannabis is efficacious in promoting sleep, deepening and lengthening the sleep cycle, and good pain relief (compared with the SSRIs and SNRIs).
Purpose: This study aimed to use the World Health Organization Quality of Life Bref questionnaire (WhoQoL-bref) to characterize the impact of Cannabis Treatment initiation on the quality of life in women suffering from treatment-resistant fibromyalgia.
Methods: A prospective cohort study involving 30 women aged 18-70 years old diagnosed with fibromyalgia, exhausted pharmacological fibromyalgia treatment, and started Cannabis treatment. Pregnant women were excluded. WhoQoL-bref was filled before Cannabis treatment initiation and 1 month following treatment.
Results: Women’s average age was 46 years (±5), with a poor general quality of life (1.47 ± 0.63), poor general health (1.47 ± 0.78), pain and discomfort, and dependence on medication (3.77 ± 1.3 and 3.07 ± 1.74, respectively) prior to Cannabis intervention. Cannabis treatment for 30 days showed a marked improvement in general quality of life (1.97 scores, p < 0.01), general health (1.83, p < 0.01), physical health (1.5, p < 0.01), and psychological domain (1.3, p < 0.01). Financial resources and home environment were not influenced by cannabis treatment (p = 0.07, p = 0.31, respectively).
Conclusion: Results suggest a potentially significant role of Cannabis in treatment-resistant Fibromyalgia women. Early Cannabis treatment may result in a beneficial short-term effect on the quality of life through its influence on pain, sleep, and physical and psychological domains. Further studies are still indicated to understand this potential and its long-term beneficial impact.
Keywords: cannabis, fibromyalgia, pain, quality of life, treatment, woman.
© 2022 The Authors. Pain Practice published by Wiley Periodicals LLC on behalf of World Institute of Pain.
References
REFERENCES
-
- Martinez-Lavin MJ. Fibromyalgia: when distress becomes (un) sympathetic pain. Pain Res Treat. 2012;2012:981565.
-
- Khurshid H, Qureshi IA, Jahan N, Went TR, Sultan W, Sapkota A, et al. A systematic review of fibromyalgia and recent advancements in treatment: is medicinal cannabis a new Hope? Cureus. 2021;13(8):e17332.
-
- Galvez-Sanchez CM, Reyes Del Paso GA. Diagnostic criteria for fibromyalgia: critical review and future perspectives. J Clin Med. 2020;9(4):1219.
-
- Creed F. A review of the incidence and risk factors for fibromyalgia and chronic widespread pain in population-based studies. Pain. 2020;161(6):1169-76.
-
- Hernando-Garijo I, Jimenez-Del-Barrio S, Mingo-Gomez T, Medrano-de-la-Fuente R, Ceballos-Laita L. Effectiveness of non-pharmacological conservative therapies in adults with fibromyalgia: a systematic review of high-quality clinical trials. J Back Musculoskelet Rehabil. 2021;35:3-20.